BridgeBio director granted RSUs and stock options
BridgeBio Pharma director Andrew Lo reported new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma director Andrew Lo reported new equity awards. He received 3,990 restricted stock units of Common Stock and now directly holds 18,079 common shares. Separately, he indirectly holds 50,583 common shares jointly with another holder.
Lo was also granted stock options for 5,277 shares of Common Stock at an exercise price of $68.92 per share, expiring on June 21, 2036. Both the RSUs and the stock options vest in full on June 22, 2027, as long as he continues serving on BridgeBio’s board of directors through that date.
Insider Trade Summary
Grant/Award: 9,267 shares
Grant/Award
3 txns
Insider
Lo Andrew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,277 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,990 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,277 contracts (Direct);
Common Stock — 18,079 shares (Direct);
Common Stock — 50,583 shares (Indirect, By Andrew W. Lo and Nancy N. Lo JTWROS)
Footnotes (3)
- F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Key Figures
RSU grant: 3,990 units
Stock options granted: 5,277 options
Option exercise price: $68.92 per share
+4 more
7 metrics
RSU grant
3,990 units
Restricted stock units granted on June 22, 2026
Stock options granted
5,277 options
Right to buy Common Stock, granted June 22, 2026
Option exercise price
$68.92 per share
Conversion or exercise price for 5,277 options
Option expiration
June 21, 2036
Expiration date of stock options
Direct common shares after grant
18,079 shares
Total direct Common Stock holdings following transactions
Indirect common shares
50,583 shares
Indirectly held jointly as JTWROS
RSU vesting date
June 22, 2027
Full vesting date for 3,990 RSUs, board service required
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, vest in full, +1 more
5 terms
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
vest in full financial
"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service."
JTWROS financial
"By Andrew W. Lo and Nancy N. Lo JTWROS"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BridgeBio (BBIO) director Andrew Lo receive in this Form 4 filing?
Andrew Lo received 3,990 restricted stock units and stock options for 5,277 shares of BridgeBio Common Stock. These awards are compensation-related grants rather than open-market purchases or sales of existing shares.
When do Andrew Lo’s new BridgeBio (BBIO) RSUs and options vest?
Both the 3,990 RSUs and the stock options for 5,277 shares vest in full on June 22, 2027, provided Andrew Lo continues serving on BridgeBio’s board of directors through that vesting date.
What is the exercise price and expiration date of Andrew Lo’s BridgeBio stock options?
The newly granted stock options cover 5,277 shares of BridgeBio Common Stock at an exercise price of $68.92 per share. These options expire on June 21, 2036, if not exercised earlier and subject to plan terms.
Are Andrew Lo’s BridgeBio equity grants open-market buys or routine awards?
The filing describes the 3,990 RSUs and 5,277 stock options as grants or awards under BridgeBio’s 2021 Amended and Restated Stock Option and Incentive Plan, indicating routine compensation awards rather than open-market buying or selling.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates